# Moderna, Inc. (MRNA) FY2026 Q1 Balance Sheet

- Company: Moderna, Inc. (MRNA)
- Period: As of 2026-03-31
- Filing: Q1 FY2026 10-Q, filed 2026-05-01, accession number 0001682852-26-000060
- Page: https://plicit.ai/financials/mrna/fy2026-q1-balance-sheet
- Chart image: https://plicit.ai/charts/mrna-fy2026-q1-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-03-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 11,488,000,000 US dollars
- **Current assets**: 5,770,000,000 US dollars
- **Non-current assets**: 5,718,000,000 US dollars
- **Liabilities**: 4,080,000,000 US dollars
- **Current liabilities**: 2,395,000,000 US dollars
- **Non-current liabilities**: 1,685,000,000 US dollars
- **Equity**: 7,408,000,000 US dollars
- **Investments**: 3,297,000,000 US dollars
- **Cash and cash equivalents**: 1,908,000,000 US dollars
- **Prepaid expenses and other current assets**: 348,000,000 US dollars
- **Inventory**: 146,000,000 US dollars
- **Accounts receivable, net**: 71,000,000 US dollars
- **Investments, non-current**: 2,251,000,000 US dollars
- **Property, plant and equipment, net**: 2,086,000,000 US dollars
- **Right-of-use assets, operating leases**: 706,000,000 US dollars
- **Other non-current assets**: 675,000,000 US dollars
- **Accrued liabilities**: 1,912,000,000 US dollars
- **Other current liabilities**: 220,000,000 US dollars
- **Accounts payable**: 161,000,000 US dollars
- **Deferred revenue**: 102,000,000 US dollars
- **Operating lease liabilities, non-current**: 645,000,000 US dollars
- **Long-term debt**: 590,000,000 US dollars
- **Other non-current liabilities**: 283,000,000 US dollars
- **Deferred revenue, non-current**: 154,000,000 US dollars
- **Financing lease liabilities, non-current**: 13,000,000 US dollars
- **Retained earnings**: 5,880,000,000 US dollars
- **Additional paid-in capital**: 1,503,000,000 US dollars
- **Accumulated other comprehensive income**: 25,000,000 US dollars
- **Preferred stock, par value $0.0001; 162 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued or outstanding at March 31, 2026 and December 31, 2025**: 0 US dollars
- **Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2026 and December 31, 2025; 397 and 394 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively**: 0 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.